#DESTINY-Breast05 trial #GBG103 at #ESMO2025: T-DXd as a potential new #SOC?

The phase III study demonstrated statistically significant and clinically meaningful improvement in #IDFS #DFS with #T-DXd vs #T-DM1 in pts with high-risk #HER2-positive eBC who had residual invasive disease.

#PostAmerica Day 266:

As Isreal celebrates the return of their loved ones, thousands of Palestinians are desperately trying to find their dead children under the rumble left behind from #Netanyahu and the #IDFs genocide.

#Ukrainian and #Moldovan law enforcement officers conducted a special operation "#Avengers", during which mercenaries of "#Wagner" and other #IDFs who fought against #Ukraine were detained

Three of the detainees are citizens of #Moldova. From 2014 to 2023, they participated in the battle for

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer | NEJM Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death...

📚The New England Journal of Medicine: A análise final do estudo #KATHERINE confirma que o #T-DM1 adjuvante melhora a #OS e a #IDFS em pacientes com câncer de mama
HER2-positivo residual, comparado ao trastuzumabe, com um perfil de segurança aceitável. www.nejm.org/doi/full/10....